NAMS Stock Forecast & Price Target

NewAmsterdam Pharma Co is viewed positively because obicetrapib has repeatedly delivered meaningful LDL reductions, with prior studies suggesting a 40% LDL lowering could translate into a 20% lower MACE risk. The company’s 9,500-patient outcomes trial is described as >90% powered to show a 20% risk reduction, while more complex modeling implies a ~98% PoS on MACE-4 and even a 99% conditional power under conservative assumptions. Beyond efficacy, a clean safety profile, convenient oral QD dosing, and a large unmet need among patients who do not reach cholesterol goals or cannot tolerate statins support a potential multi-billion-dollar commercial opportunity.

NewAmsterdam Pharma Co is viewed negatively because its value hinges on PREVAIL, where a slower-than-expected event rate led to a 4Q26 interim analysis and only a roughly 25-40% Bayesian/conditional probability of success after about 400 MACE-3 events, leaving meaningful execution risk if stopping criteria are not met and the study runs to 4Q27. The investment case is further weakened by class risk from prior CETP inhibitor failures, uncertainty that LDL-C reductions will translate into meaningful MACE benefit, and competitive pressure after recent launches and setbacks in the field. With no revenues, ongoing R&D funding needs, and composition-of-matter patent protection expiring in 2027, downside to around cash, or about $4/sh, remains a credible outcome if efficacy, safety, reimbursement, or commercialization disappoint.